GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (NAS:NYXH) » Definitions » Loans Receivable

NYXH (Nyxoah) Loans Receivable : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nyxoah Loans Receivable?

Nyxoah's Loans Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.


Nyxoah Loans Receivable Historical Data

The historical data trend for Nyxoah's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyxoah Loans Receivable Chart

Nyxoah Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial - - - - -

Nyxoah Quarterly Data
Jun19 Dec19 Mar20 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nyxoah Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Nyxoah Loans Receivable Related Terms

Thank you for viewing the detailed overview of Nyxoah's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Nyxoah Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.